Related Experiment Video

Updated: Jul 5, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Targeting Ras in myeloid leukemias

Benjamin S Braun1, Kevin Shannon

  • 1Department of Pediatrics, University of California, San Francisco, CA 94143, USA. braunb@peds.ucsf.edu <braunb@peds.ucsf.edu>

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|April 17, 2008
PubMed

Insights

Ras proteins are crucial for cell signaling and are frequently mutated in cancers. This review explores strategies to target these mutations, particularly in myeloid malignancies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Ras proteins are key signal transducers activated by cell surface receptors.
  • Oncogenic mutations in Ras genes occur in ~30% of human cancers.
  • Activating KRAS and NRAS mutations are prevalent in pancreatic, lung, colon cancers, and myeloid leukemia.

Purpose of the Study:

  • To review general strategies for targeting hyperactive Ras signaling in cancer.
  • To focus on the application of these strategies in myeloid malignancies.

Main Methods:

  • Literature review of Ras signaling pathways.
  • Analysis of oncogenic mutations in KRAS and NRAS.
  • Discussion of therapeutic approaches targeting Ras.

Main Results:

  • Ras signaling is a critical pathway in cancer development.
  • Specific Ras mutations drive various cancer types, including myeloid leukemia.
  • Targeting Ras offers a promising therapeutic avenue.

Conclusions:

  • Hyperactive Ras signaling presents a viable target for cancer therapy.
  • Developing strategies to inhibit Ras is essential for treating cancers with Ras mutations.
  • Further research into Ras-targeted therapies, especially for myeloid malignancies, is warranted.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...